Bryan Kipp - Revvity Senior Licensing
| RVTY Stock | 111.11 0.23 0.21% |
Executive
Bryan Kipp is Senior Licensing of Revvity
| Address | 940 Winter Street, Waltham, MA, United States, 02451 |
| Phone | 781 663 6900 |
| Web | https://www.revvity.com |
Revvity Management Efficiency
The company has return on total asset (ROA) of 0.0172 % which means that it generated a profit of $0.0172 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0331 %, meaning that it created $0.0331 on every $100 dollars invested by stockholders. Revvity's management efficiency ratios could be used to measure how well Revvity manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Revvity's Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.06 in 2024, whereas Return On Capital Employed is likely to drop 0.02 in 2024. At this time, Revvity's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 11.1 B in 2024, whereas Other Current Assets are likely to drop slightly above 172.7 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Michael Johnson | IDEXX Laboratories | 46 | |
| Sarah Demey | Neogen | N/A | |
| Peter Aggersbjerg | Mettler Toledo International | 56 | |
| Steve Tucker | Aclaris Therapeutics | N/A | |
| Bill Waelke | Neogen | N/A | |
| Joseph JD | Charles River Laboratories | 50 | |
| James Thorburn | Twist Bioscience Corp | 68 | |
| Michael Fero | Twist Bioscience Corp | N/A | |
| Stephany Foster | Qiagen NV | 45 | |
| Thomas Ebeling | Qiagen NV | 61 | |
| MD MBA | Aclaris Therapeutics | N/A | |
| Nicholas Childs | IQVIA Holdings | N/A | |
| Ross Levine | Qiagen NV | 49 | |
| Kevin Balthaser | Aclaris Therapeutics | 36 | |
| Antonio Santos | Qiagen NV | N/A | |
| Kerry Bennett | IDEXX Laboratories | N/A | |
| JeanPascal Viola | Qiagen NV | N/A | |
| Amy Rocklin | Neogen | 52 | |
| Thomas Neidert | Qiagen NV | N/A | |
| Christos Ross | Waters | N/A | |
| Jim Berkshire | IQVIA Holdings | N/A | |
Management Performance
| Return On Equity | 0.0331 | ||||
| Return On Asset | 0.0172 |
Revvity Leadership Team
Elected by the shareholders, the Revvity's board of directors comprises two types of representatives: Revvity inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Revvity. The board's role is to monitor Revvity's management team and ensure that shareholders' interests are well served. Revvity's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Revvity's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joel Goldberg, General Administration | ||
| Jayashree Thacker, Senior Officer | ||
| Madhuri FACMG, Senior Officer | ||
| Bryan Kipp, Senior Licensing | ||
| Andrew Okun, Chief VP | ||
| Miriame Victor, Senior Officer | ||
| Magali Four, Senior Officer | ||
| Stephen Willoughby, Senior ESG | ||
| Tajinder Vohra, Senior Operations | ||
| Prahlad Singh, President CEO | ||
| Robert Friel, Advisor | ||
| Maxwell Krakowiak, Senior CFO | ||
| Masoud Toloue, VP Diagnostics | ||
| Daniel Tereau, Senior Development | ||
| Arvind SundarRajan, Vice Technology |
Revvity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Revvity a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0331 | ||||
| Return On Asset | 0.0172 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 15.64 B | ||||
| Shares Outstanding | 121.7 M | ||||
| Shares Owned By Insiders | 0.20 % | ||||
| Shares Owned By Institutions | 91.86 % | ||||
| Number Of Shares Shorted | 4.2 M | ||||
| Price To Book | 1.71 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Revvity Stock Analysis
When running Revvity's price analysis, check to measure Revvity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revvity is operating at the current time. Most of Revvity's value examination focuses on studying past and present price action to predict the probability of Revvity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revvity's price. Additionally, you may evaluate how the addition of Revvity to your portfolios can decrease your overall portfolio volatility.